Study to Evaluate t(11;14) Status and BCL2 Expression in Adult Participants With Multiple Myeloma (MM)
NCT ID: NCT04721002
Last Updated: 2023-10-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
514 participants
OBSERVATIONAL
2021-07-07
2023-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Approximately 500 adult participants with newly confirmed or relapsed/refractory (R/R) multiple myeloma (MM) will be enrolled in around 15-20 countries.
Participants will receive standard of care while participating in this study. No drug will be administered as a part of this study.
Participants will attend regular visits during the course of the study at a hospital or clinic and will be asked to provide bone marrow and blood samples.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With Relapsed/Refractory (R/R) Multiple Myeloma
NCT04178902
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
NCT01478048
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
NCT06953960
A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets
NCT05308654
Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma
NCT03361748
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Participants With Multiple Myeloma
Participants with newly diagnosed and relapsed/refractory multiple myeloma will receive standard of care. Bone marrow and blood samples will be collected.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AbbVie
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
ABBVIE INC.
Role: STUDY_DIRECTOR
AbbVie
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tulane School of Medicine /ID# 223864
New Orleans, Louisiana, United States
University of Texas Southwestern Medical Center /ID# 223865
Dallas, Texas, United States
Hospital Italiano de Buenos Aires /ID# 224153
Ciudad Autonoma Buenos Aires, Buenos Aires F.D., Argentina
Alfred Health /ID# 224386
Melbourne, Victoria, Australia
Hospital São Rafael /ID# 224307
Salvador, Estado de Bahia, Brazil
Hospital de Clinicas de Porto Alegre /ID# 224274
Porto Alegre, Rio Grande do Sul, Brazil
Clinica Sao Germano /ID# 224239
São Paulo, São Paulo, Brazil
Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein /ID# 224303
São Paulo, São Paulo, Brazil
Instituto COI de Educacao e Pesquisa /ID# 224245
Rio de Janeiro, , Brazil
Real e Benemérita Associação Portuguesa de Beneficência /ID# 224305
São Paulo, , Brazil
Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo /ID# 225749
São Paulo, , Brazil
Cross Cancer Institute /ID# 224172
Edmonton, Alberta, Canada
Klinicki bolnicki centar Zagreb /ID# 226969
Zagreb, City of Zagreb, Croatia
Fakultni nemocnice Hradec Kralove /ID# 224089
Hradec Králové, , Czechia
Fakultni nemocnice Ostrava /ID# 224090
Ostrava, , Czechia
CHRU Lille - Hopital Claude Huriez /ID# 228919
Lille, Hauts-de-France, France
CHU de Nantes, Hotel Dieu -HME /ID# 223702
Nantes, Pays de la Loire Region, France
AP-HP - Hopital Necker /ID# 228062
Paris, , France
Praxis am Volkspark /ID# 224763
Berlin, , Germany
Asklepios Klinik Altona /ID# 224761
Hamburg, , Germany
Alexandra General Hospital /ID# 224828
Athens, Attica, Greece
Beaumont Hospital /ID# 225514
Beaumont, Dublin, Ireland
Hadassah Medical Center-Hebrew University /ID# 224884
Jerusalem, Jerusalem, Israel
Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona /ID# 224690
Ancona, , Italy
ASST Grande Ospedale Metropolitano Niguarda /ID# 224608
Milan, , Italy
Maastricht Universitair Medisch Centrum /ID# 224694
Maastricht, , Netherlands
Rikshospitalet OUS HF /ID# 227288
Oslo, , Norway
Szpital Kliniczny im. Heliodora Swiecickiego Uniwersytetu Medycznego im. Karola /ID# 227038
Poznan, Greater Poland Voivodeship, Poland
Instytut Hematologii i Transfuzjologii /ID# 227039
Warsaw, Masovian Voivodeship, Poland
Institutul Clinic Fundeni /ID# 224574
Bucharest, București, Romania
Princess Noorah Oncology Center /ID# 224968
Jeddah, , Saudi Arabia
Univ Medical Ctr Ljubljana /ID# 225408
Ljubljana, , Slovenia
Hospital Universitario Germans Trias i Pujol /ID# 229281
Badalona, Barcelona, Spain
Hospital Clinic de Barcelona /ID# 224804
Barcelona, , Spain
Hospital de Leon /ID# 229191
León, , Spain
Hospital Universitario Fundacion Jimenez Diaz /ID# 229524
Madrid, , Spain
Hospital Universitario 12 de Octubre /ID# 225617
Madrid, , Spain
Hospital Universitario de Salamanca /ID# 224803
Salamanca, , Spain
Taichung Veterans General Hospital /ID# 227084
Taichung, , Taiwan
Bagcilar Medipol Mega Universite Hastanesi /ID# 225515
Istanbul, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H20-126
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.